checkAd
AlsterResearch Update: Synbiotic - Legalisation of cannabis

AlsterResearch Update: Synbiotic - Legalisation of cannabis

The future governing parties in Germany want to legalise the sale of cannabis for recreational use. The politicians have agreed on this in a published coalition agreement.

The full update is avaible on:

Read

 

What’s it all about?

The future governing parties in Germany want to legalise the sale of cannabis for recreational use. The politicians have agreed on this in a published coalition agreement. Accordingly, a controlled distribution of cannabis to adults in licensed shops is part of this agreement. Synbiotic as a unique and broadly diversified player with a clear focus on cannabis and cannabinoids should benefit from legalisation in many ways, even if some uncertainties remain. Nevertheless, the potential legalisation of cannabis is a hot topic and bodes well to the equity story of Synbiotic. We therefore see in this thematic issue the potential for a rerating of the stock, and which thus might close the gap towards our fair value calculation. We keep our BUY recommendation and PT unchanged at EUR 37.00.

SynBiotic Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Wertpapier



0 Kommentare
Nachrichtenquelle: AlsterResearch AG
25.11.2021, 16:39  |  254   |   |   

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

AlsterResearch Update: Synbiotic - Legalisation of cannabis The future governing parties in Germany want to legalise the sale of cannabis for recreational use. The politicians have agreed on this in a published coalition agreement. Accordingly, a controlled distribution of cannabis to adults in licensed shops is part of this agreement.

Nachrichten des Autors

Titel
Titel
Titel
Titel